Count What Matters: Advanced Metrics to Value a Pharma Patent Portfolio Before the Generic Cliff
Pharma patent portfolios don’t fail because the patents are “bad.”
They fail because the valuation is.
Most teams still price patent assets like they’re static—counting patents, listing jurisdictions, and assuming that more coverage automatically means…
